China has approved a new weight-loss drug that is poised to rival Novo Nordisk and Eli Lilly's popular GLP-1 treatments, ...

The MHRA has revealed it's received more than 560 reports of acute pancreatitis in patients taking GLP-1 injections since ...

New Delhi: India plans to roll-out a nationwide screening programme for measuring obesity among school children officials aware of the matter said. Children will be measured for their waist-to-hip ...

Find insight on Innovent Biologics, Fisher & Paykel Healthcare and more in the latest Market Talks covering Health Care.

These popular medications are now at the center of a major weight loss drug lawsuit. Find out which drugs and involved and ...

With the recent approval in China of Innovent Biologics' (OTCPK:IVBIY) mazdutide as the first-ever dual GLP-1/glucagon ...

These can include weight loss, loss of appetite, yellowing of the skin, vomiting or nausea, and the symptoms of diabetes ...

CVS adds Wegovy to its top formularies and bolsters its Weight Management program, aiming to expand access while cutting costs.

Lifestyle therapy may not be enough to improve outcomes for patients with HF and obesity, but careful risk evaluation and ...

Novo Nordisk just killed its deal with Hims & Hers. But Hims might come out stronger after this development. Read why the ...

Hardman Johnston Global Advisors, an investment management company, released its “Hardman Johnston Global Equity Strategy” ...

Novo Nordisk A/S and Eli Lilly & Co, the pharmaceutical giants dominating ... product revenue of 704 million Danish kroner ($110 million) in China to Wegovy’s local launch. Lilly has said it plans to ...